Rocky Mountain Diagnostic Solutions

PRECISE  ·  TIMELY  ·  LOCAL

$13.91B US Drug Testing Market
24 Hour Turnaround Time
68% Blended Gross Margin
$500K Seed Raise

INVESTOR PRESENTATION  ·  2026

The Problem

The incumbents dominate through inertia, not performance.

3–7 Day Turnaround

Quest and LabCorp deliver results in 3–7 days. Hiring managers need faster turnaround.

No Local Presence

No personal contact, no visibility into specimen status, no urgency to perform.

Lost Productivity

Employees leave the worksite for testing — hours lost on company time.

772,800 pre-employment screens in Colorado annually

The Solution

Mobile collection. In-house CLIA lab. Same-day results.

01

We Come to You

DOT-certified collector at your worksite. Minimal employee downtime.

02

In-House CLIA Lab

Specimens processed in our CLIA moderate-complexity lab — no send-out delays.

03

Same-Day Results

Presumptive results same day. Confirmation in 24 hours.

04

Personal Point of Contact

A real person you can call. Not a 1-800 number.

Market & Competitive Edge

$13.91B
US drug testing market (2025)
34%
Projected market growth 2025–2030
772,800
CO pre-employment screens / year
Exclusive
Only mobile collection provider with an in-house lab in Colorado
Quest / LabCorp Aggregators RMDS
Turnaround Time 3–7 Days 48–72 hrs Same Day
Worksite Collection Sometimes
In-House CLIA Lab
Personal Contact
Gross Margin ~50% ~45% 68–78%

70% of Colorado volume is non-DOT — higher margin, less regulatory friction

Subscription bundles deliver stable recurring revenue from Day 1

Financials

RATE CARD

Tier Price COGS Margin
Headline 10-panel $120 $27 78%
Lab 5-panel $75 $22 71%
Contracted Samples 20–99/yr $75 $26 65%
Contracted Samples 100+/yr $65 $26 60%
DOT 5-panel + EBT $85 $52 39%
73–78% In-house margin
68% Blended margin
~$75 Per-test contrib

REVENUE PROJECTIONS

$799K
Year 1
$1.69M
Year 2
$2.12M
Year 3
Metric Yr 1 Yr 2 Yr 3
Revenue $799K $1.69M $2.12M
Gross Margin 78% 76–78% 76–78%
Net Income $384K $1.10M $1.40M
Break-even Mo. 5

The Team

Two equal co-founders. Complementary expertise. Fully committed.

JK
Jake Kammerer
Co-Founder

Extensive background in real estate with a proven ability to manage critical timelines and close deals. Transitioned into the substance use disorder field, developing deep operational knowledge including client acquisition, compliance culture, and stakeholder relationships.

CW
Chet Wood
Co-Founder

With a foundation in recovery leadership and high-stakes decision-making, Chet understands that accurate, timely testing isn't just operational, it's consequential. He leads client relationships with sharp attention to detail, ensuring every employer gets a compliant, dignified process from start to finish.

The Ask

Raising $500,000 · Priced equity (SAFE available) · Terms negotiable

Raise Amount $500,000
Structure SAFE Note (terms negotiable)
Equity & Terms Negotiable by investment size

USE OF FUNDS

Working Capital — 12-Month Payroll $200,000
Lab Equipment (Analyzer Lease) $116,000
Reagent + Supplies (3 months) $60,000
Legal, CLIA Application, Insurance $31,000
Founder / Operating Buffer $35,000
Recruiting, Software, Contingency $58,000
TOTAL $500,000

WHAT YOUR INVESTMENT FUNDS

CLIA lab online Month 3 — 2-hr turnaround on non-regulated specimens
Two analyzers on lease — redundancy from Day 1
W-2 collector team + Lab Technologist, 12 months funded
Path to $1.69M Yr 2 / $2.12M Yr 3 at 76–78% gross margin
Enterprise exit value $10M–$16M based on industry comps
Rocky Mountain Diagnostic Solutions

Let's Talk.

We'd welcome a 30-minute walkthrough of our financials, path to launch and pricing strategy.

Jake Kammerer
Co-Founder
jake@rmdsco.com 206.579.5168

ROCKY MOUNTAIN DIAGNOSTIC SOLUTIONS, INC.  ·  DENVER, COLORADO